Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 5/20 | 0.49 |
| ▸ | VIPR2 | P41587 | 5/20 | 0.48 |
| ▸ | NPY4R | P50391 | 8/20 | 0.48 |
| ▸ | NPY1R | P25929 | 6/20 | 0.48 |
| ▸ | NPY2R | P49146 | 4/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.48 |
| ▸ | VIPR1 | P32241 | 4/20 | 0.48 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.48 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29649781 | 0.96 | AGTR2 (0.51) | GLP1RVIPR2NPY4RNPY1RNPY2R | |
| SCHEMBL29649899 | 0.90 | NPY4R (0.52) | GLP1RNPY4RNPY1RNPY2RNPY5R | |
| Angiotensin-Ii SCHEMBL29973063 | 0.90 | AGTR2 (0.62) | AGTR1AGTR2 | |
| SCHEMBL30026320 | 0.88 | C5AR1 (0.51) | GLP1RVIPR2NPY4RNPY1RNPY2R | |
| SCHEMBL31064947 | 0.88 | BACE1 (0.55) | GLP1RVIPR2NPY4RNPY1RNPY2R | |
| Talfirastide SCHEMBL15926158 | 0.87 | AGTR1 (0.59) | AGTR1AGTR2 | |
| SCHEMBL30293824 | 0.87 | GLP1R (0.40) | GLP1RVIPR2NPY4RNPY1RNPY2R | |
| SCHEMBL29602482 | 0.87 | NPY4R (0.59) | NPY4RNPY1RNPY2RNPY5RAGTR1 | |
| SCHEMBL29609505 | 0.87 | NPY4R (0.59) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30331687 | 0.86 | NPY4R (0.49) | GLP1RNPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | CAPACITY BIO INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12343331-B2 | Methods and agents that stimulate mitochondrial turnover for treating disease | Capacity Bio, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| EP-4284779-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-117120417-A | Methods and agents for stimulating mitochondrial turnover to treat diseases | 容量生物公司 | 2023-11-24 | — | — | CN | disclosed |
| WO-2022165189-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-20220233507-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. | 2022-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12343331-B2 | Methods and agents that stimulate mitochondrial turnover for treating disease | NLN, MAVS, PINK1 | GLP1R 272/4885VIPR2 287/4885NPY4R 295/4885 |
| US-20220233507-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | NLN, MAVS, PINK1 | GLP1R 272/4885VIPR2 287/4885NPY4R 295/4885 |
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | MDH2, NLN, PINK1 | GLP1R 1390/4885VIPR2 1818/4885NPY4R 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.